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Cardiomyocyte-speciﬁc deﬁciency of ketone
body metabolism promotes accelerated
pathological remodeling
Rebecca C. Schugar 1, Ashley R. Moll 1, D. André d’Avignon 2, Carla J. Weinheimer 1, Attila Kovacs 1,
Peter A. Crawford 1,3,*
ABSTRACT
Objective: Exploitation of protective metabolic pathways within injured myocardium still remains an unclariﬁed therapeutic target in heart
disease. Moreover, while the roles of altered fatty acid and glucose metabolism in the failing heart have been explored, the inﬂuence of highly
dynamic and nutritionally modiﬁable ketone body metabolism in the regulation of myocardial substrate utilization, mitochondrial bioenergetics,
reactive oxygen species (ROS) generation, and hemodynamic response to injury remains undeﬁned.
Methods: Here we use mice that lack the enzyme required for terminal oxidation of ketone bodies, succinyl-CoA:3-oxoacid CoA transferase
(SCOT) to determine the role of ketone body oxidation in the myocardial injury response. Tracer delivery in ex vivo perfused hearts coupled to
NMR spectroscopy, in vivo high-resolution echocardiographic quantiﬁcation of cardiac hemodynamics in nutritionally and surgically modiﬁed
mice, and cellular and molecular measurements of energetic and oxidative stress responses are performed.
Results: While germline SCOT-knockout (KO) mice die in the early postnatal period, adult mice with cardiomyocyte-speciﬁc loss of SCOT
(SCOT-Heart-KO) remarkably exhibit no overt metabolic abnormalities, and no differences in left ventricular mass or impairments of systolic
function during periods of ketosis, including fasting and adherence to a ketogenic diet. Myocardial fatty acid oxidation is increased when
ketones are delivered but cannot be oxidized. To determine the role of ketone body oxidation in the remodeling ventricle, we induced
pressure overload injury by performing transverse aortic constriction (TAC) surgery in SCOT-Heart-KO and aMHC-Cre control mice. While
TAC increased left ventricular mass equally in both groups, at four weeks post-TAC, myocardial ROS abundance was increased in
myocardium of SCOT-Heart-KO mice, and mitochondria and myoﬁlaments were ultrastructurally disordered. Eight weeks post-TAC, left
ventricular volume was markedly increased and ejection fraction was decreased in SCOT-Heart-KO mice, while these parameters remained
normal in hearts of control animals.
Conclusions: These studies demonstrate the ability of myocardial ketone metabolism to coordinate the myocardial response to pressure
overload, and suggest that the oxidation of ketone bodies may be an important contributor to free radical homeostasis and hemodynamic
preservation in the injured heart.
 2014 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Keywords Myocardial ketone body metabolism; Nuclear magnetic resonance (NMR) measurement of substrate metabolism; Ventricular
remodeling; Oxidative stress; Mitochondrial metabolism
1. INTRODUCTION
During evolution of adverse ventricular remodeling that culminates in
cardiomyopathy and congestive heart failure, myocardial fuel utilization
becomes inefﬁcient and inﬂexible, and mechanistic studies in pre-
clinical models indicate that altered substrate and energy meta-
bolism can cause cardiomyopathy [1e5]. Therefore, deeper under-
standing and ultimately, judicious nutritional and pharmacological
manipulation of myocardial metabolism are expected to improve
morbidity and mortality attributable to heart failure [6,7]. While the
roles of the primary myocardial fuels, fatty acids and glucose, in
myocardial homeostasis and disease have been explored extensively,
the inﬂuence of myocardial ketone bodies, considered a secondary
substrate class due to their low circulating concentrations in fed states,
remains ill-deﬁned. However, ketone bodies are highly competitive
substrates for myocardial oxidative metabolism, and ketone bodies
1Department of Medicine, Center for Cardiovascular Research, Washington University, St. Louis, MO, USA 2Department of Chemistry, Washington University, St. Louis, MO,
USA 3Department of Genetics, Washington University, St. Louis, MO, USA
*Corresponding author. Present address: Sanford-Burnham Medical Research Institute, 6400 Sanger Rd., Orlando, FL 32827, USA. Tel.: þ1 407 745 2135. E-mail:
pcrawford@sanfordburnham.org (P.A. Crawford).
Received July 3, 2014  Revision received July 19, 2014  Accepted July 23, 2014  Available online 13 August 2014
http://dx.doi.org/10.1016/j.molmet.2014.07.010
Original article
754 MOLECULAR METABOLISM 3 (2014) 754e769  2014 The Authors. Published by Elsevier GmbH. This is an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.
0/).
www.molecularmetabolism.com
circulate at increased concentrations in the setting of heart failure, at
concentrations directly proportional to severity of the cardiomyopathy
[8e10].
The liver is the source of the circulating ketone bodies D-b-hydrox-
ybutyrate (D-bOHB) and acetoacetate (AcAc), whose myocardial
oxidation requires the mitochondrial matrix enzyme succinyl-CoA:3-
oxoacid-CoA transferase (SCOT, encoded by nuclear Oxct1), which
as the only CoA transferase encoded by the mammalian genome,
uniquely catalyzes a near-equilibrium reaction that transfers coenzyme
A (CoA) between AcAc and succinate (see Ref. [11] for a recent review
on integrated ketone body metabolism). Congenital and ubiquitous
absence of SCOT causes signiﬁcant morbidity in humans [12], and is
incompatible with neonatal life in mice [13]. SCOT is absolutely
required for terminal oxidation of ketone bodies [13], and through its
ability to inﬂuence succinate metabolism, the reaction it catalyzes
directly interfaces with the tricarboxylic acid (TCA) cycle and the
electron transport chain [11]. Consequently its ability to inﬂuence
myocardial bioenergetics may transcend physiological states consid-
ered ‘ketotic’.
The heart is the highest ketone body consumer per unit mass, oxidizing
ketone bodies in proportion to their delivery at the expense of fatty acid
oxidation and glucose oxidation [14e19]. Compared with fatty acid
oxidation, ketone bodies are more energetically efﬁcient, yielding more
energy available for ATP synthesis per molecule of oxygen invested
[20e22]. Furthermore, the oxidation of ketone bodies may attenuate
ROS production associated with the oxidation of fatty acids [21e23]
suggesting that myocardial ketone body oxidation could protect
against injury and adverse ventricular remodeling responses, which
promote the development of cardiomyopathy and heart failure [24].
Indeed, clinical data suggest that myocardial ketone body metabolism
may serve as an important therapeutic target. At least a subset of
patients diagnosed with SCOT-deﬁciency exhibited dilated cardiomy-
opathy on presentation [25e28]. Moreover, extraction of delivered
ketone bodies is maintained in failing hearts, but not skeletal muscle,
of humans with advanced heart failure [29]. Similarly, the contribution
of ketone bodies to cardiac energy metabolism may be elevated in
patients with dilated and hypertrophic cardiomyopathies [30]. These
results suggest that the diminution of myocardial fatty acid oxidation
that typically occurs during the evolution of advanced cardiomyopathy
may not be coupled to reduction of ketone body oxidation [1,2,5]. It is
unclear whether maintained, or even elevated, utilization of ketone
bodies preserves cardiac function, is a pathologic consequence, or is
an innocent bystander in the adversely remodeling heart.
Therefore, mechanistic studies using tissue-selective genetic rodent
models will begin to establish when and whether myocardial ketone
body metabolism may be protective or deleterious to the heart. Here,
we sought to investigate the role of ketone utilization in the heart
during periods of myocardial stress by using mice with cardiomyocyte-
speciﬁc loss of SCOT (SCOT-Heart-KO) to determine the physiological
and pathological responses of myocardium lacking the ability to utilize
ketones as an energy source.
2. MATERIALS AND METHODS
2.1. Animals and diets
The Animal Studies Committee at Washington University approved all
experiments prior to their performance. SCOT-Heart-KO mice were
generated by successive generations of breeding of Oxct1ﬂox/ﬂox mice
to mice expressing Cre recombinase under control of the alpha myosin
heavy chain promoter (aMHC-Cre, Jackson Laboratory, stock number
011038) [31]. SCOT-Heart-KO and aMHC-Cre control mice (male mice
were studied) were maintained for at least ten generations on a C57BL/
6N C57BL/6J hybrid substrain background. A few experiments were
performed using a tamoxifen inducible SCOT-Heart-KO strain that was
generated by breeding Oxct1ﬂox/ﬂox mice to mice expressing tamoxifen
inducible Cre recombinase under control of the aMHC promoter
(MerCreMer, Jackson Laboratory, stock number 005657). To induce
knockdown of SCOT in the cardiomyocytes of adult mice, tamoxifen
(20 mg/kg) was administered intraperitoneally for 21 d. Mice were
maintained on Lab Diet (5053) ad libitum and autoclaved water on
cedar chip bedding at 22 C. Lights were off between 1800 and 0600.
Food was removed and fresh bedding was provided at the onset of
fasting for mice fasted for 24 h; water was provided ad libitum to
fasting animals. For some studies, mice were maintained on a rodent
ketogenic diet (Harlan-Teklad TD.110633), which was described
previously in Ref. [32] and is comprised of 94.1% fat, 4.6% protein,
and 1.3% carbohydrate. The contributing fat sources are lard and
milkfat; casein is the protein source, and sucrose is the minimal
carbohydrate source; the diet is deﬁcient in choline. A cohort of mice
was also maintained on a 40% fat diet (Harlan-Teklad TD.110290),
which is comprised of 40.7% fat, 40.3% carbohydrate, and 19%
protein, in which lard and milkfat are the fat sources, casein is the
protein source, and sucrose (18.3% by mass) and cornstarch are the
carbohydrate sources.
2.2. Metabolite and insulin measurements
Serum samples were acquired from animals that had been fasted for
4 h on fresh cedar chip bedding. Serum glucose, D-bOHB, total ketone
bodies (TKB, D-bOHB plus AcAc), triacylglycerols (TAG), and insulin
concentrations were measured as previously described in Ref. [33].
2.3. Langendorff heart perfusions
Mouse heart perfusions were performed as previously described in
Ref. [33]. Brieﬂy, SCOT-Heart-KO and aMHC-Cre mice received
100 units of heparin by intraperitoneal injection and 10 min later were
anesthetized with an intraperitoneal injection of 390 mg/kg sodium
pentobarbital. Hearts were excised and placed in ice-cold Krebs-
Henseleit (KH) bicarbonate solution (118 mM NaCl, 25 mM NaHCO3,
4.7 mM KCl, 0.4 mM KH2PO4, 2.5 mM CaCl2, pH 7.4) supplemented
with 5 mM glucose. Hearts were cannulated via the aorta and then
perfused in the Langendorff mode at a constant pressure of 60 mmHg,
with continuous bubbling of a 95% O2/5% CO2 gas mixture into the
KH-bicarbonate buffer with 3% fatty acid free bovine serum albumin
(BSA). Experimental perfusion conditions are described in the legends
for Figures 1 and 2. Insulin used for all perfusions was human insulin
(rDNA origin; Lilly).
2.4. NMR spectroscopy of myocardial extracts
After 20 min of perfusion, freeze-clamped (liquid N2-cooled tongs)
hearts were homogenized in 3.6% perchloric acid, followed by removal
of precipitated debris and pH neutralization of the supernatant with
KOH. Neutralized perchloric acid tissue extracts were dissolved in
310 mL of D2O (Cambridge Isotope Laboratories) spiked with 1 mM
trimethylsilyl propionate (TSP), which provides a chemical shift refer-
ence and an internal concentration standard to quantify extract
metabolite concentrations. Extracts were transferred into thin-walled
5 mm NMR tubes (Shigemi) and proﬁled using 13C-edited proton nu-
clear magnetic resonance (NMR) measured at 11.75 T (Varian/Agilent
Direct Drive-1) via ﬁrst increment gradient heteronuclear single-
quantum correlation (gHSQC) as previously described in Refs.
[13,31,33,34], obtaining integrals for carbon #4 of glutamate, carbon
#2 of taurine, carbon #3 of lactate, carbons #2/#3 of succinate, carbon




#3 of alanine, and carbon #6 of 2-deoxyglucose-6-phosphate. For
quantiﬁcation of 13C-enrichment of carbons #1 and #5 of glutamate
from [1-13C]acetate (Figure 2I), band-selective heteronuclear multiple
quantum coherence (HMBC) experiments were carried out on heart
tissue extracts following perfusion. Samples were prepared by dis-
solving dried extracts in 280 mL of D2O followed by pH correction to
near 7.0 by addition of KOH. The extract solutions were charged into
5 mm matched susceptibility plug Shigemi tubes prior to analysis, and
data were collected at 25 C. Experiments were conﬁgured to selec-
tively monitor two-bond 1He13C correlations between glutamate
carbon position #4 and #2 proton signals and #5 and #1 carbonyl
carbons. The carbon chemical shift (F1 domain) selectivity was
accomplished through use of adiabatic pulses and limited to 2011 Hz.
Proton acquisition in t2 was carried out for 255 ms over a spectral
width of 2376 Hz resulting in 606 complex data points. Adequate
resolution was obtained using 32 t1 increments collected in phase-
sensitive mode coupled with linear prediction in F1 prior to Fourier
transformation (2048  256; t2  t1). Adequate signal-to-noise was
obtained from 24 transients on all extract samples. Additional collec-
tion conditions include delay times of 12 s between transients, 1H 90-
degree pulse of 8 ms, 13C 90-degree pulse of 12 ms and coherence
delay time of 50 ms corresponding to a two-bond HeC coupling of
10 Hz. These conditions for glutamate result in a 2-to-1 proton
receptivity for the volume integrals resulting from glutamate carbon
positions #4 and #2, respectively, for equal 13C labeling on glutamate
carbon positions #5 and #1.
2.5. Lipopolysaccharide (LPS) injections
SCOT-Heart-KO and aMHC-Cre mice were given intraperitoneal in-
jections of 8 mg/kg of Escherichia coli 0111:B4 LPS (Sigma) sus-
pended in phosphate-buffered saline (PBS). Control cohorts received
an injection of an equal volume of PBS alone. Injections were per-
formed in the morning, and food was removed from all animals
immediately after the injections. At 6 h post-injection, LPS-induced
cardiac dysfunction was assessed by echocardiography. A separate
cohort of mice was used for serum analysis and tissue collection at 6 h
post-injection.
2.6. Transverse aortic constriction (TAC)
Surgeries were performed as described previously in Ref. [35,36].
Brieﬂy, mice were anesthetized with ketamine (100 mg/kg) and
xylazine (10 mg/kg) administered IP, and surgery was performed using
aseptic technique. Each mouse was restrained supine on a magnetic












































































































Figure 1: Myocardial SCOT expression is required for ketone body oxidation. (A) Immunoblot for ketolytic enzyme succinyl-CoA:3-oxoacid-CoA transferase (SCOT) and actin in
heart and skeletal muscle protein lysates derived from adult aMHC-Cre, Oxct1ﬂox/ﬂox, and SCOT-Heart-KO mice. Immunoblot (B) and quantiﬁcation (C) for ketolytic enzyme succinyl-
CoA:3-oxoacid-CoA transferase (SCOT) and actin in heart protein lysates derived from adult aMHC-MerCreMer and tamoxifen-inducible SCOT-Heart-KO mice following intra-
peritoneal injections of 20 mg/kg tamoxifen for 21 d. (D) 13C-edited proton NMR spectrum (2.1e2.5 ppm, relative to chemical shift of trimethylsilyl propionate internal standard)
from hearts of aMHC-Cre and SCOT-Heart-KO mice that had been perfused with a buffer containing 11 mM glucose, 20 mU/mL insulin, 0.6 mM palmitate, and 1 mM sodium
D-[2,4-13C2]bOHB for 15 min prior to collection of tissues and generation of extracts.
13C-Glutamate is a reporter of the contribution of 13C-labeled D-bOHB to TCA cycle ﬂux, and is
selectively absent in myocardial extracts from SCOT-Heart-KO mice. (E) Fractional 13C-enrichment of glutamate (a surrogate for the contribution of a 13C-labeled substrate to the
TCA cycle) in hearts of aMHC-Cre and SCOT-Heart-KO mice perfused ex vivo with a buffer containing either (i) 1.2 mM [U-13C]palmitic acid, 5 mM glucose, 1 mU/mL insulin, 1 mM
lactate and 0 mM or 1 mM unlabeled D-bOHB, or (ii) 0.6 mM [U-13C]palmitic acid, 11 mM glucose, 10 mU/mL insulin, 1 mM lactate and 0.25 mM unlabeled D-bOHB measured by
13C-edited proton NMR. n ¼ 4e9 mice/group. **p  0.01, ***p  0.001 by 1-way ANOVA with Tukey’s post hoc analysis.
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dissection through the intercostal muscles, the aorta was identiﬁed
and freed by additional blunt dissection. 7.0 silk suture was placed
around the transverse aorta and tied tightly around a blunt needle (27
gauge). The needle was then rapidly removed and the chest wall was
closed using a purse string suture. The surgical incision was closed in
two layers with an interrupted suture pattern. The mouse was kept
warm on a heating pad throughout the procedure and during recovery.
Sham-operated mice received the same surgery, except that the su-
ture was simply placed around the aorta brieﬂy, but not tied. At 4 wk or
8 wk post-surgery, cardiac function was assessed by echocardiog-
raphy. At the end of the study, mice were euthanized by CO2 inhalation
followed by cervical dislocation; hearts were removed rapidly and snap
frozen in LiN2.
2.7. Echocardiography
Echocardiography was performed using a Vevo 2100 Imaging System
(VisualSonics, Toronto, Canada) equipped with a 30 MHz linear-array
transducer. Parasternal long-axis views were obtained by a
handheld technique under 1e2% isoﬂuorane (fasting and lipopoly-
saccharide studies), or 100 mg/kg tribromoethanol (ketogenic diet,
high fat diet, sham operated, 4 wk, and 8 wk TAC studies) anesthetic
conditions. Two-dimensional and M-mode images were obtained in
the long- and short-axis views to calculate fractional shortening (FS).
Quantitative image analysis was also performed using a speckle-
tracking algorithm. In brief, suitable 2-D cine-loops were selected
from digitally acquired echocardiographic images based on adequate
visualization of the endo- and epicardial border and absence of image
artifacts. Three consecutive cardiac cycles were selected for analysis
based on image quality. Semi-automated tracing of the endocardial
and epicardial borders were performed and veriﬁed over all 3 cardiac
cycles and then corrected as needed to achieve good quality tracking
throughout each cine loop. Tracked images were then processed in a
frame-by-frame manner to derive the following parameters: left ven-
tricular (LV) volumes (end-diastolic and end-systolic, calculated by the
disk summation method); rate-of-change of LV volumes (peak positive
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Figure 2: Reconﬁgured metabolism in the absence of myocardial SCOT. (A, B) Fractional % 13C-enrichment of glutamate (glu), lactate (lac), and alanine (ala) or absolute pools of
metabolites (nmol/mg tissue) in hearts of aMHC-Cre control and SCOT-Heart-KO mice perfused ex vivo with a buffer containing 11 mM [1-13C]glucose, 20 mU/mL insulin, 0.6 mM
palmitate, 0.25 mM D-bOHB and 1 mM sodium lactate measured by 13C-edited proton NMR. (C) Myocardial glucose uptake measured by perfusing hearts with a buffer containing
1 mM [6-13C]-deoxyglucose, 20 mU/mL insulin, 0.6 mM palmitate and 1 mM sodium lactate and the phosphorylation of 2-deoxy-[6-13C]glucose was detected by 13C-edited proton
NMR. (D) Myocardial glycogen content. (E, F) Fractional 13C-enrichment of glutamate, lactate, and alanine (%), or total pools of metabolites (nmol/mg tissue) in hearts following
perfusion with 11 mM [1-13C] glucose, 20 mU/mL insulin, 0.6 mM palmitate and 0.25 mM D-bOHB, and 0 mM lactate; or (G, H) 11 mM glucose, 20 mU/mL insulin, 0.6 mM
palmitate, 0.25 mM D-bOHB and 1 mM sodium [3-13C]-lactate measured by 13C-edited proton NMR. (I) A surrogate for anaplerosis was acquired by perfusing hearts with a buffer
containing 11 mM glucose, 10 mU/mL insulin, 0.6 mM palmitate, 0.25 mM D-bOHB, 1 mM lactate and 0.25 mM sodium [1-13C]-acetate. n ¼ 5e10 mice/group. *p  0.05,
***p  0.001 by 1-way ANOVA with Tukey’s post hoc test.




systolic volume), ejection fraction (stroke volume divided by end-
diastolic volume multiplied by 100); LV mass (volume of the epicar-
dial shell minus volume of the endocardial shell multiplied by the
speciﬁc gravity of muscle); and global radial myocardial strain (aver-
aged peak segmental radial strain).
2.8. Immunoblot
Protein extracts were prepared in a buffer consisting of 20 mM Tris,
150 mM NaCl, 1 mM EDTA, 1% Triton-X 100, protease inhibitors
(Roche), and phosphatase inhibitors (Sigma), as previously described
in Ref. [19]. Immunoblots measuring myocardial carbonylated proteins
were measured using the OxyBlot Protein Oxidation Kit (Millipore).
MitoProﬁle total OXPHOS antibody cocktail (abcam) was used to
measure key proteins of the electron transport chain. Acetylated lysine
antibody (Cell Signaling) was used to measure acetylated lysine resi-
dues in myocardial and mitochondrial extracts, and succinylated lysine
antibody (PTM Biolab) was used to measure succinylated lysine resi-
dues in myocardial extracts. Band intensities were densitometrically
quantiﬁed using QuantityOne software. For myocardial extracts pre-
pared for acetylated lysine, the extract was prepared in the above
buffer with the addition of 1 mM trichostatin A, and 50 mM Sirtuin
inhibitor AGK7.
2.9. Histology and transmission electron microscopy (TEM)
Hearts from SCOT-Heart-KO and aMHC-Cre mice after 4 wk TAC
(n ¼ 2/group) were ﬁxed in a modiﬁed Karnovsky’s ﬁxative of 3%
glutaraldehyde and 1% paraformaldehyde in 0.1 M sodium cacodylate
buffer for at least 24 h, followed by a post-ﬁx in 2% osmium tetroxide
in 0.1 M sodium cacodylate buffer for 1 h prior to en bloc staining with
2% aqueous uranyl acetate for 30 min, dehydration in graded ethanols
and embedding in PolyBed 812 (Polysciences, Hatﬁeld, PA). Tissue
blocks were sectioned at 90 nm thickness, then stained with Venable’s
lead citrate and viewed with a JEOL model 1400EX electron micro-
scope (JEOL, Tokyo). Digital images were acquired using the Gatan
Orius (Gatan, Warrendale, PA) high deﬁnition CCD, 11 megapixel TEM
camera.
For light microscopy, hearts were collected from mice immediately
post-sacriﬁce and ﬁxed in 10% neutral buffered formalin. Tissue was
embedded in parafﬁn, microtome-sectioned, stained with hematoxylin
and eosin, and imaged using a Zeiss Axioskop microscope and Axio-
Vision software (version 4.7, San Diego, CA).
2.10. Mitochondrial isolation
Whole hearts were excised, washed, atria were removed, and ven-
tricular tissue minced on ice as previously described in Ref. [19].
Mitochondrial isolation medium (MIM; 300 mM sucrose, 0.2 mM EDTA,
10 mM Na HEPES, pH 7.4) and bovine pancreatic trypsin [0.125 mg/
mL trypsin; speciﬁc activity  9000 Na-Benzoyl-L-Arginine Ethyl Ester
(BAEE) units/mg protein; Sigma] was added to digest the tissue for
15 min at 4 C, followed by the addition of equal volumes MIM con-
taining BSA (1 mg/mL) and soybean trypsin inhibitor (0.65 mg/mL) to
halt the digestion. The samples were then rapidly homogenized on ice
by using a Glas-Col dounce homogenizer, and centrifuged at 600  g
for 10 min at 4 C in MIM buffer containing BSA (MIM-BSA; 1 mg/mL).
The resulting supernatant, which contained mitochondria, was spun at
8000  g for 15 min at 4 C, the supernatant discarded, the mito-
chondrial pellet re-suspended in 10 mL of ice-cold MIM þ BSA, and
the sample centrifuged again at 8000  g for 15 min at 4 C. The
pellet was brieﬂy washed in ice-cold MIM and each tissue sample was
resuspended in 75 mL of ice-cold MIM (pH 7.2). For mitochondria
isolated for immunoblots, the ﬁnal pellet was resuspended in 75 mL of
protein lysis buffer containing protease inhibitors, phosphatase in-
hibitors, 1 mM trichostatin A, and 50 mM Sirtuin inhibitor AGK7.
2.11. Mitochondrial respiration
Immediately following mitochondrial isolation, total protein was
quantiﬁed by Bradford assay (Bio-Rad). Respiration was quantiﬁed at
37 C using a water-jacketed Clark Electrode (Hansatech Instruments)
under conditions described previously in Ref. [37]. Brieﬂy, 0.5 mg of
mitochondria were added to 1 mL of respiration buffer [125 mM KCl,
20 mM HEPES, 3 mM Mg-acetate, 0.4 mM EGTA, 0.3 mM dithiothreitol
(DTT), 5 mM KH2PO4, 0.2% BSA, pH 7.1] containing either 20 mM
palmitoyl-L-carnitine and 5 mM malate or 5 mM succinate and 10 mM
rotenone. The solubility of oxygen in the respiration buffer at 37 C was
235 nmol O2 per mL. Following measurement of basal (state 2)
respiration, 1 mM ADP was added to the respiration chamber, and
maximal (state 3) respiration quantiﬁed. Thereafter, state 4 (F1F0
ATPase-independent) respiration was measured by adding 1 mg/mL
oligomycin (Sigma) to inhibit F1F0 ATP synthase. Uncoupled respiration
was measured following the addition of 5 mM carbonyl cyanide 4-
(triﬂuoromethoxy)phenylhydrazone (FCCP) where applicable.
2.12. Tissue triglyceride, glycogen, and nicotinamide metabolite
quantiﬁcations
Myocardial triglycerides, using a Folch extract of heart and biochemical
quantiﬁcation, were quantiﬁed as previously described in Ref. [19].
Myocardial glycogen and NADþ(H) concentrations were measured in
heart lysates using ﬂuorescent biochemical assays (Biovision).
2.13. Quantiﬁcation of H2O2 production
Mitochondria were added to an incubation buffer containing 125 mM
KCl, 4 mM KH2PO4, 20 mM HEPES, pH 7.2, 1 mM MgCl2, 0.2% fatty
acid free bovine serum albumin, and 20 mM EGTA, as well as 100 mM
Amplex Red and 100 mU horseradish peroxidase (Amplex Red
Hydrogen Peroxide/Peroxidase Assay Kit, Invitrogen), and ﬂuorescence
was measured (Ex 560 nm, Em 590 nm). After several baseline ac-
quisitions, sodium succinate was added to a ﬁnal concentration of
10 mM to induce H2O2 production. Other substrate combinations
included 10 mM succinate plus 1 mM D-bOHB, and 10 mM succinate
plus 1 mM AcAc (base hydrolyzed from ethyl AcAc, see Ref. [34] for
details). After 5 min, 0.5 mM rotenone was added to attenuate H2O2
production from reverse electron transport.
2.14. CellROX quantiﬁcation of tissue superoxide
The CellROX Green reagent detects superoxide localized within the
mitochondria and nuclei by binding to DNA after reacting with su-
peroxide, while CellROX Deep Red reagent detects ROS localized in
the cytoplasm in living cells, and total tissue superoxide content in
fresh tissue harvested from the animal. CellROX quantiﬁcation of
tissue superoxide levels were performed in fresh-frozen (in Optimal
Cutting Temperature medium) left ventricular cryosections following
incubation for 30 min at 37 C using a ﬁnal concentration of each
CellROX dye of 5 mM (n ¼ 3 hearts/condition). All slides were
examined and images were acquired at 0.5 mm slice thickness using
a Zeiss LSM 700 confocal microscope and Zeiss Zen software. All
images were acquired using the same gain measurement. Using
ImageJ, CellROX intensity was quantiﬁed in at least 3  20 ﬁelds
per mouse.
2.15. Statistical analyses
Analyses were performed with GraphPad 5.0 software (Prism, San
Diego, CA), using tests described within the text and ﬁgure legends.
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3.1. Remodeled substrate preference and intermediary metabolism
in hearts of SCOT-Heart-KO mice
Despite increased ketone body delivery in mice maintained on a high
fat, low carbohydrate ketogenic diet, myocardial expression of the
enzyme uniquely required for ketone body oxidation, succinyl-CoA:3-
oxoacid-CoA transferase (SCOT), and intrinsic myocardial capacity to
oxidize ketone bodies are surprisingly both decreased [33]. Further-
more, the normal ability of ketone bodies to suppress myocardial fatty
acid oxidation is abrogated [33]. To determine whether diminished
ketolytic capacity during periods of increased ketosis confers salutary
or detrimental hemodynamic effects, in vivo hemodynamic function
was quantiﬁed by echocardiography in wild-type mice maintained on a
commonly studied ketogenic diet for 4 wk (Table 1). In accordance
with our previous studies [32,33], serum D-bOHB concentrations were
elevated nearly 10-fold by ketogenic diet feeding, compared with mice
fed standard chow, and normal weight gain in chow-fed mice was
attenuated by the ketogenic diet. While no overt alterations in cardiac
hemodynamic function were detected in ketogenic diet-fed mice,
echocardiographic analysis revealed several modest but signiﬁcant
alterations including reduced heart rate and a concomitantly increased
left ventricular ejection time (Table 1). Indeed, D-bOHB has been
demonstrated to decrease sympathetic outﬂow and may explain the
reduced heart rate of mice maintained on this ketogenic diet [38].
While this experiment demonstrates the absence of deleterious he-
modynamic effects of ketogenic diet-induced partial impairment of
ketolytic capacity, the hemodynamic and metabolic effects of complete
loss of the ability to metabolize ketone bodies in the heart have not
been determined. In the mouse heart this may be particularly impor-
tant, because as much as 34% of myocardial oxidative metabolism
proceeds through ketone body oxidation [39]. Because germline
deletion of SCOT results in neonatal lethality [13], mice with
cardiomyocyte-speciﬁc loss of SCOT (SCOT-Heart-KO) were developed
using an aMHC-Cre driver strain [31]. SCOT-Heart-KO mice are viable
and lack SCOT protein and enzyme activity speciﬁcally in the
myocardium, while SCOT is retained in other ketolytic tissues such as
skeletal muscle (Figure 1A). Because aMHC gene expression is acti-
vated during embryonic development [40], phenotypes of adult SCOT-
Heart-KO mice may be muted by compensatory metabolic changes
elicited in the developmental or neonatal stages, and thus a tamoxifen-
inducible SCOT-Heart-KO mouse strain was also generated by
crossing Oxct1ﬂox/ﬂox mice to the aMHC-MerCreMer transgenic strain
to explore the effects of SCOT deﬁciency following deletion in adult
mice for a subset of experiments (Figure 1B,C, Table 2).
Using ex vivo Langendorff heart perfusions and 13C-edited proton
nuclear magnetic resonance (NMR) spectroscopy, we conﬁrmed that
hearts of adult SCOT-Heart-KO mice are unable to terminally oxidize
D-[13C]bOHB (Figure 1D). Moreover, suppression of the contribution of
13C-labeled fatty acid-derived acetyl-CoA to the tricarboxylic acid
(TCA) cycle by ketone bodies is abrogated in perfused hearts of
SCOT-Heart-KO mice, indicating unrestrained fatty acid oxidation
under perfusion conditions mimicking both the fed (0.25 mM D-bOHB)
and fasted (1 mM D-bOHB) states (Figure 1E). 13C-labeled glucose
metabolism was also quantiﬁed in hearts of SCOT-Heart-KO mice
using perfusion buffers in the presence of the anaplerotic (i.e., in-
termediates supplied to the TCA cycle independent of citrate syn-
thase) substrate lactate (1 mM). The procession of glucose through
glycolysis yields pyruvate, which is predominantly channeled via (i)
decarboxylation by pyruvate dehydrogenase, forming acetyl-CoA for
entry into the TCA cycle via citrate synthase, (ii) carboxylation,
forming the TCA cycle intermediate malate or oxaloacetate (ana-
plerotic reactions catalyzed by malic enzymes and pyruvate carbox-
ylase, respectively), (iii) reduction to lactate via lactate
dehydrogenase, a reversible NADþ/NADH-coupled redox reaction, or
(iv) transamination to alanine. Compared to hearts of aMHC-Cre
control mice, no differences in 13C-enrichment of glutamate from
[1-13C]glucose (fractional 13C-enrichment of glutamate serves as a
quantitative surrogate for [13C]acetyl-CoA procession through citrate
synthase [41]) were observed, nor were there differences in the 13C-
enrichments of lactate or alanine (Figure 2A). While extracts derived
from perfused hearts from SCOT-Heart-KO mice exhibited modestly
larger alanine pools (Figure 2B), no differences in relative lactate/
alanine ratios were observed, suggesting normal NADþ/NADH redox
couple balance in hearts of SCOT-Heart-KO mice under these
perfusion conditions. Loss of SCOT did not inﬂuence glucose uptake,
as measured by accumulation of phosphorylated 2-deoxy-[6-13C]
glucose, or baseline steady-state glycogen content (Figure 2C, D).
To determine if lactate included in the perfusion buffer concealed
metabolic reprogramming in the SCOT-Heart-KO heart, [1-13C]glucose
was perfused in the absence of exogenous unlabeled lactate. While
13C-enrichment of glutamate remained normal in hearts of SCOT-
Heart-KO mice (Figure 2E), SCOT deﬁciency in myocardium was
associated with a signiﬁcant attenuation in de novo formation of 13C-
lactate. Total endogenous myocardial lactate pools were also lower in
SCOT-Heart-KO mice under these perfusion conditions, while lactate/
alanine ratios remained normal (Figure 2F). To determine if the
decreased lactate abundance in hearts of SCOT-Heart-KO mice was
associated with increased lactate oxidation, we performed parallel
perfusions in which the buffer components were identical to previous
perfusions that included 1 mM lactate, but in which [3-13C]lactate was
used instead of unlabeled lactate, and unlabeled glucose was used
instead of [1-13C]glucose. No differences in fractional 13C-enrichment
of glutamate from [3-13C]lactate were observed, suggesting that the
oxidation of lactate is similar between SCOT-Heart-KO and aMHC-Cre
mice (Figure 2G). Taken together, given decreased channeling of
glucose metabolites to lactate, only in the absence of exogenous
lactate, these results suggest that hearts of SCOT-Heart-KO mice may
be particularly poised to channel lactate-derived pyruvate to
anaplerosis.
Table 1 e Echocardiographic and metabolic responses of wild-type mice
following 4 wk on ketogenic diet.
Chow Ketogenic Diet
Serum D-bOHB, mM 0.17  0.03 1.81  0.50**
Body weight, g, initiation of study 20.5  0.5 20.8  0.8
Body weight, g, after 4 wk on diet 22.9  0.9 18.9  1.3*
Heart rate, bpm 488  16.6 414  17.8*
LVIDd, mm 3.98  0.06 3.82  0.07
LVIDs, mm 2.92  0.05 2.74  0.11
LVMI, mg/mm tibial length 5.08  0.19 4.77  0.39
E, mm/s 641  22.9 687  42.8
A, mm/s 537  25.1 453  45.7
E/A 1.20  0.04 1.57  0.16*
DT, ms 20.3  2.1 20.2  1.5
IVRT, ms 15.2  0.6 16.6  1.1
E0, mm/s 22.9  1.2 19.5  1.6
A0 , mm/s 22.8  1.09 16.0  1.03**
E/E0 28.4  2.1 35.8  2.4*
FS, % 0.27  0.01 0.28  0.02
S0 , mm/s 15.7  1.1 15  1.0
IVCT, ms 11.0  0.8 11.6  1.7
ET, ms 43.4  0.5 48.9  0.6***
*p  0.05; **p  0.01; ***p  0.001. n ¼ 5/group.




Therefore, to quantify whether the SCOT deﬁciency is associated with
altered anaplerosis, hearts were perfused with [1-13C]acetate, and
positional enrichment of glutamate was quantiﬁed. [1-13C]acetate la-
bels glutamate on carbon position #5 during the ﬁrst turn of the TCA
cycle, and carbon position #1 on subsequent turns of the TCA cycle,
but 13C-enrichment on carbon #1 is diluted in proportion to the
magnitude of TCA cycle anaplerosis [42]. SCOT deﬁciency in the
myocardium was associated with a signiﬁcantly increased ratio of
carbon #5/carbon #1, suggesting an increased rate of anaplerosis in
hearts of SCOT-Heart-KO mice under baseline perfusion conditions
(Figure 2I). No differences in abundances of mRNA transcripts for
anaplerotic enzymes pyruvate carboxylase or the three malic enzymes
were observed (data not shown).
3.2. Normal hemodynamic responses to ketosis in SCOT-Heart-KO
mice
Acutely, cardiomyocytes oxidize ketone bodies in proportion to their
delivery, at the expense of fatty acid oxidation and glucose oxidation.
Because SCOT-Heart-KO mice exhibit increased contribution from fatty
acids to the TCA cycle, we determined the impact of SCOT deﬁciency in
the myocardium in the setting of fasting, a state in which glucose
availability decreases, delivery of ketone bodies to the myocardium
increases, and myocardial lipid delivery and storage increases [43].
Following a 24 h fast, no alterations of systolic function were observed
in SCOT-Heart-KO mice (Table 2), and fasting to 48 h failed to reveal
any difference in myocardial triglyceride content between SCOT-Heart-
KO mice and aMHC-Cre controls (1.32 0.4 and 1.33 0.2 mg/mg of
tissue, respectively). While a modest reduction in heart rate was
observed in tamoxifen-inducible SCOT-Heart-KO mice that were fasted
for 24 h, no differences in fractional shortening or LV mass were
observed (Table 2).
To determine if more prolonged ketosis could induce signiﬁcant
adverse remodeling in hearts that lacked the ability to oxidize ketone
bodies, we fed aMHC-Cre control and SCOT-Heart-KO mice a keto-
genic diet for 12 wk. Heart weights, normalized to tibia length, were
normal in SCOT-Heart-KO mice maintained on this diet, and serum
ketone and glucose concentrations were unchanged compared to
ketogenic diet-fed control mice (Supplemental Table 1). To determine
if an adverse myocardial response to ketosis in SCOT-Heart-KO could
be triggered by preceding caloric overload and weight gain, aMHC-Cre
control and SCOT-Heart-KO mice were maintained on a sucrose-
enriched 40% fat diet for 12 wk, and then switched to a ketogenic
diet for 6 wk. As expected, the calorically enriched diet caused a
marked weight gain in both groups, and the transition to the ketogenic
diet caused a marked and equal weight loss between groups. Heart
weights, normalized to tibia length, were normal in SCOT-Heart-KO
mice following adherence to this diet, and serum ketone and
glucose concentrations were not different between aMHC-Cre control
and SCOT-Heart-KO mice (Supplemental Table 1), indicating that
ketosis is well-tolerated by the heart even when ketone body oxidation
is abrogated.
3.3. Myocardial stress induces structural and hemodynamic
abnormalities in hearts of SCOT-Heart-KO mice
Because of (i) the successful adaptation of SCOT-Heart-KO mice to
ketotic intervals that are normally associated with increased myocar-
dial fatty acid and ketone body oxidation, and (ii) the increased frac-
tional contribution of fatty acid oxidation to energy economy in the
hearts of these knockout animals, we hypothesized that the pre-
existing reliance on fatty acids for bioenergetic needs in hearts of
SCOT-Heart-KO mice may cause an adverse response to conditions
that normally cause the heart to become less reliant on fat oxidation
and more dependent on glucose utilization. A robust mediator of the
systemic inﬂammatory response, lipopolysaccharide (LPS), normally
suppresses myocardial fatty acid oxidation and promotes cardiac
dysfunction [44]. After LPS administration to SCOT-Heart-KO and
aMHC-Cre control mice, echocardiography revealed that SCOT-Heart-
KO mice exhibited moderately impaired fractional shortening at 6 h
post-injection compared to LPS-injected aMHC-Cre control mice and
to saline-injected SCOT-Heart-KO mice (Table 2), suggesting that
SCOT-Heart-KO mice may have an impaired ability to adapt to path-
ological conditions that decrease fatty acid oxidation.
A common injurious myocardial stress is sustained hypertension,
which in mice is experimentally mimicked by provoking cardiac
pressure overload through surgical transverse aortic constriction (TAC).
This procedure provokes metabolic abnormalities that precede and
drive adverse ventricular remodeling [5,45]. To determine the effect of
SCOT deﬁciency on pathological remodeling in response to pressure
overload, TAC (and sham) surgeries were performed in SCOT-Heart-KO
and aMHC-Cre control mice, and echocardiographic assessments
were performed following 4 wk and 8 wk TAC. Myocardial abundance
of SCOT did not signiﬁcantly change in control animals at 4 wk or 8 wk
following TAC surgery (Supplemental Figure 1). Moreover, serum ke-
tone body concentrations did not differ between SCOT-Heart-KO and
aMHC-Cre mice after 4 wk TAC, nor did they increase from their
respective baseline values; however, serum glucose concentration was
modestly elevated after 4 wk TAC in SCOT-Heart-KO mice
(Supplemental Table 2). While TAC-induced increases in left ventricular
mass were comparable between SCOT-Heart-KO mice and aMHC-Cre
control mice at both time points (Figure 3A), mean pressure gradient
Table 2 e Echocardiographic analysis post-metabolic stress.
Baseline 24 h Fast 24 h Fast Tamoxifen-inducible Lipopolysaccharide
Genotype aMHC-Cre SCOT-Heart-KO aMHC-Cre SCOT-Heart-KO aMHC-MerCreMer TamInd-SCOT-Heart-KO aMHC-Cre SCOT-Heart-KO
Heart rate, bpm 517.8  39.4 471.2  15.2 451.6  11.0 434.4  5.6 461.8  13.2 407.4  10.3* 556.7  9.7 581.5  22.2##
LVIDd, mm 4.0  0.2 4.2  0.1 3.9  0.1 4.0  0.1 4.2  0.1 4.2  0.1 3.5  0.1 3.7  0.1##
LVMI, mg/g body
weight
4.0  0.1 4.2  0.4 4.3  0.2 4.3  0.1 5.1  0.3 5.1  0.2 4.1  0.2 4.2  0.1
FS, % 30.2  1.1 27.3  1.1 31.4  2.5 28.8  1.7 25.0  2.4 24.4  1.5 27  1.6 22.3  1.6*,#
*p < 0.05 compared to control group, same condition.
#p < 0.05 compared to baseline condition, same genotype.
##p < 0.01 compared to baseline condition, same genotype.
n ¼ 5e6/group.
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across the aortic arch was decreased after 8 wk TAC in SCOT-Heart-
KO mice, suggesting decreased contractility and abnormal emptying of
the left ventricle (Figure 3B). Furthermore, while aMHC-Cre mice
maintained preserved systolic function with increased myocardial wall
thickness relative to LV chamber size, SCOT-Heart-KO mice exhibited
left ventricular dilation with increased end diastolic volume
(2.9  0.4 mL/mm tibia length and 5.3  1.0 mL/mm tibia length,
respectively; p ¼ 0.04; n ¼ 7e10/group) and decreased relative wall
thickness (Figure 3C, D). In addition, systolic function was markedly
decreased in hearts of pressure-overloaded SCOT-Heart-KO mice
(ejection fractions of 35.0  7.0%, versus 54.9  6.0% in aMHC-
Cre control mice; p ¼ 0.03; n ¼ 7e10/group) (Figure 3D). No sta-
tistically signiﬁcant differences in cardiac output or evidence of
worsened pulmonary edema were detected in the SCOT-Heart-KO
mice after 8 wk TAC (Supplemental Table 3). Light microscopic
analysis of hearts post-TAC revealed no differences in inﬂammatory
inﬁltrate at either time point (Figure 3E), or in extent of collagen
deposition (data not shown). To determine if the accelerated pressure
overload-induced ventricular remodeling phenotype could be linked to
ultrastructural abnormalities, transmission electron micrographs from
SCOT-Heart-KO and aMHC-Cre hearts were compared. Mitochondrial
number, organization, and ultrastructural integrity were normal in
sham-operated SCOT-Heart-KO mice (Figure 4AeF). Conversely,
extensive myoﬁbrilar disarray and Z-line thickening were observed
after 4 wk TAC, uniquely within cardiomyocytes from SCOT-Heart-KO
mice (Figure 4H, K). High power images revealed no overt differences
in mitochondrial ultrastructure relative to aMHC-Cre control mice
(Figure 4I, L). Lower power electron micrographs suggest a modest
increase in mitochondrial number, with more disordered packing,
among myoﬁbrils of SCOT-Heart-KO cardiomyocytes following 4 wk
TAC (Figure 4G, J). Quantiﬁcation of mitochondrial genome copy
number indicated a trend towards increased mitochondrial number in
hearts of SCOT-Heart-KO mice following 4 wk TAC (Figure 5A, B).
Additionally, increased myocardial abundance of the mRNA encoding
mitochondrial transcription factor A (TFAM, a mitochondrial tran-
scription factor that coordinates mitochondrial genome replication) was
observed in hearts of SCOT-Heart-KO mice following 4 wk TAC
(Figure 5C). While phosphorylation of the energy sensor AMPK was
normal at baseline and following 4 wk TAC in hearts of SCOT-Heart-KO
mice, after 8 wk TAC relative abundance of phosphorylated AMPK was
moderately increased in extracts from (Supplemental Figure 2), sug-
gesting delayed energy deﬁcit that was not primarily caused by the
absence of ketone body oxidation.
The ultrastructural abnormalities observed following 4 wk TAC in
myocardium of SCOT-Heart-KO mice that preceded hemodynamic or
structural abnormalities led us to quantify mitochondrial bioenergetics
at baseline and following 4 wk TAC. To determine if the modest in-
crease in mitochondrial number may be a compensatory mechanism
for abnormal mitochondrial respiratory function, respiration was
quantiﬁed in mitochondria isolated from hearts of 4 wk sham-operated
and post-TAC mice. Substrates palmitoyl-L-carnitine/malate (PLC-M
donate electrons to Complexes I and II of the electron transport chain),
and succinate/rotenone (S/R, rotenone is a Complex I inhibitor,
allowing electrons from succinate to be delivered selectively to Com-
plex II) were tested in independent runs. Mitochondria isolated from
hearts of sham SCOT-Heart-KO mice using either PLC-M or S/R
revealed no differences in rates of oxygen consumption at state 2
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Figure 3: SCOT deﬁciency is associated with worsened pathological remodeling following pressure overload surgery. SCOT-Heart-KO mice and aMHC-Cre controls underwent
transverse aortic constriction (TAC) surgery to promote pressure overload-induced pathological remodeling and were analyzed following either 4 wk or 8 wk TAC. (A) Left ventricular
mass (LVM) index, mg LV/mm tibia length; (B) Mean pressure gradient across the aortic arch, mmHg; (C) LV relative wall thickness (RWT); and (D) end diastolic volume (EDV) index,
mL/mm tibia length, and ejection fraction, %, were all assessed by echocardiography. n ¼ 5e10 mice/group. *p  0.05, **p  0.01 compared to aMHC-Cre mice at same time
point; #p  0.05, ##p  0.01, ###p  0.001, ####p  0.0001 compared to baseline time point by 2-way ANOVA with Bonferroni post hoc analysis (E) Representative H&E stained
heart cross sections and higher power images. Scale bars are 50 mM.




inhibited) or during uncoupled respiration (provoked by addition of the
ionophore FCCP) compared with mitochondria prepared from aMHC-
Cre control mice (Figure 5D, E). Furthermore, while S/R-dependent
state 2 respiration was decreased for both SCOT-Heart-KO and
aMHC-Cre control mitochondria following 4 wk TAC relative to their
sham counterparts, PLC-M-dependent state 2 respiration was rela-
tively increased in mitochondria isolated from 4 wk TAC hearts of
SCOT-Heart-KO mice, compared with mitochondria prepared from
hearts of 4 wk TAC aMHC-Cre control mice. Comparing mitochondria
isolated from hearts of sham animals to 4 wk TAC hearts, PLC-M and
S/R-dependent state 3 respiration was decreased in both genotypes,
reﬂecting a decrease in ATP synthesis following pressure overload as
demonstrated previously in Ref. [46,47], but no differences in state 3
respiration were observed in mitochondria from SCOT-Heart-KO mice.
Furthermore, no differences in myocardial protein abundance of the
subunits of the electron transport chain including ATP5A (a subunit of
the ATPase F1 catalytic core), between hearts of SCOT-Heart-KO and
aMHC-Cre mice following either 4 wk or 8 wk TAC (Supplemental
Figure 3) were observed. Finally, no differences in NADþ, NADH,
NADt or the NADþ/NADH ratio were observed in myocardial extracts
from SCOT-Heart-KO mice from the sham or 4 wk TAC conditions
(Figure 5F, G). Taken together, these results indicate that despite
pressure overload-induced abnormalities of myocyte ultrastructure and
mitochondrial packing, SCOT-Heart-KO mice exhibit no overt signs of
impaired mitochondrial respiration or cellular redox potential.
3.4. Diminished myocardial protein acetylation and increased
myocardial ROS in pressure overloaded remodeling hearts of SCOT-
Heart-KO mice
Loss of the ability to transfer CoA from succinate to AcAc eliminates
one cellular source of acetyl-CoA, which not only serves as a substrate
for terminal oxidation in the TCA cycle, but also as a chemical substrate
for post-translational modiﬁcation of numerous structural proteins and
enzymes in mitochondrial and cytoplasmic compartments, signiﬁcantly
inﬂuencing their downstream functions [48]. To determine if loss of
SCOT in cardiomyocytes is associated with a change in abundance of
acetylated lysine residues among myocardial proteins we performed
immunoblots of myocardial and isolated mitochondrial isolates using
an antibody raised against acetylated lysine. At baseline, abundance of
acetylated proteins was modestly, but nearly signiﬁcantly decreased in
total myocardial extracts (Figure 6A). Mitochondria isolated from
SCOT-Heart-KO and aMHC-Cre control hearts at baseline did reveal














Figure 4: Pressure overload-induced ultrastructural abnormalities SCOT-Heart-KO mice. (A, B, D, E) Lower power transmission electron microgrpahs reveal normal cardiac muscle
structure in sham operated SCOT-Heart-KO mice. (C, F) High power images show no differences in mitochondrial ultrastructure between genotypes. (G, H, J, K) Following 4 wk
TAC, the structural integrity of the myocardium appears compromised in SCOT-Heart-KO mice with evident breakdown of the myoﬁbrils as well as thickening of the Z-lines. (I, L)
Despite myoﬁbrilar disarray, mitochondrial ultrastructure appears to be preserved in SCOT-Heart-KO mice. Scale bars are 2 mm (panels A, D, G, J), 1 mM (B, E, H, K), and 200 nm
(C, F, I, L). n ¼ 2 mice/group.
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signiﬁcant diminution in content of acetylated lysine in knockout
mitochondria (Figure 6B). Moreover, total myocardial extracts prepared
following 4 wk TAC also demonstrated a signiﬁcant reduction in the
quantity of acetylated lysine residues in hearts isolated from SCOT-
Heart-KO mice (Figure 6C).
Lysine residues are modiﬁed by numerous post-translational modi-
ﬁcations in addition to acetylation, and individual lysine residues may
be acetylated or succinylated [49]. Because SCOT transfers CoA
between succinate and AcAc, loss of SCOT could theoretically alter
the pools of succinate/succinyl-CoA available for numerous down-
stream reactions, including succinylation of lysine residues. To
determine myocardial succinate concentrations in SCOT-Heart-KO
mice, we quantiﬁed its pool sizes by NMR in ex vivo perfused
hearts, and observed that total myocardial succinate content was
commensurate with that of control mice (Supplemental Figure 4A, B).
However, when lactate was omitted from the perfusion buffer the
myocardial succinate pool size was signiﬁcantly diminished in SCOT-
Heart-KO mice (Supplemental Figure 4C), consistent with reduced
concentrations of other metabolites under this perfusion condition
(see Figure 2E, F). A modest trend towards diminished abundance of
succinylated lysine residues was also observed in unperfused
myocardial extracts prepared following 4 wk TAC (Supplemental
Figure 4D). Taken together, loss of SCOT may yield modest
context-selective diminution of the succinate pool size, but decreased
lysine acetylation in SCOT-Heart-KO myocardium is unlikely to be
attributable to increased lysine succinylation.
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Figure 5: Relative genome content and respiration studies of cardiac mitochondria. (A, B) Quantiﬁcation of mitochondrial genome copy number (relative abundance) by qPCR using
puriﬁed heart gDNA from SCOT-Heart-KO and aMHC-Cre mice at baseline, or after 4 wk or 8 wk TAC. Data are presented as means  SEM; n ¼ 4e5/group, *p  0.05 by 1-way
ANOVA with Tukey’s post hoc analysis. (C) Increased myocardial expression of mitochondrial transcription factor A (Tfam). (D, E) Respiration rates in the basal leak condition (state
2), ADP-stimulated condition (state 3), F1F0-ATPase independent condition (state 4, oligomycin), and uncoupled condition (FCCP) in mitochondria isolated from left ventricles of
SCOT-Heart-KO and aMHC-Cre mice using palmitoyl-L-carnitine and malate or succinate and rotenone as substrates at (D) baseline or (E) following 4 wk TAC. Data are presented
as means  SEM; n ¼ 4e7 mice/group, *p  0.05, ***p  0.001 by 2-way ANOVA with Bonferroni post hoc analysis. (F, G) No differences in NADþ, NADH, NADt or NADþ/NADH
ratios were detected when comparing whole myocardial lysates of SCOT-Heart-KO and aMHC-Cre control mice at (F) baseline or (G) after 4 wk TAC. n ¼ 5e7 mice/group.




Deacetylation of speciﬁc electron transport chain subunits, including
NDUFS1 of complex I and the Rieseke subunit of cytochrome bc1, have
been shown to attenuate ROS generation in the setting of ischemia/
reperfusion injury [50]. Moreover, procession of ketone bodies through
the SCOT enzyme toward terminal oxidation attenuates ROS production
from oxidation of fatty acids [21e23]. Therefore, we hypothesized that
loss of SCOT activity would be associated with increased mitochondrial
ROS production, augmenting injury and remodeling responses,
particularly in the setting of pressure overload-induced remodeling.
Mitochondrial oxidative metabolism via the electron transport chain is
the major source of ROS within cardiomyocytes [23,51]. To determine
if the SCOT deﬁciency and increased reliance on oxidation of fatty acids
was associated with increased mitochondrial ROS production, mito-
chondria isolated from hearts of SCOT-Heart-KO and aMHC-Cre mice
were incubated with 10 mM succinate, succinate plus 1 mM D-bOHB,
or succinate plus 1 mM AcAc, and H2O2 emission was quantiﬁed as a
reporter of mitochondrial superoxide production. While no difference in
the rates of H2O2 production between the two genotypes was
observed, independent of SCOT genotype, addition of 1 mM AcAc to
the substrate buffer signiﬁcantly diminished rates of H2O2 production
compared to mitochondria incubated with succinate alone, or succi-
nate plus D-bOHB (Figure 7A).
To determine the impact of SCOT deﬁciency on tissue ROS abundance,
superoxide was quantiﬁed in situ using ﬂuorescent probes. In fresh
frozen myocardial sections prepared from sham-operated animals,
myocardial superoxide content was normal, while fresh frozen
myocardial sections from 4 wk TAC hearts revealed signiﬁcantly
increased total superoxide accumulation, and a trend towards
increased mitochondrial/nuclear superoxide accumulation was evident
in myocardial sections prepared from SCOT-Heart-KO mice
(Figure 7B). Increased ROS levels may lead to oxidative protein damage
including protein carbonylation, and the oxidation of protein residues
can be detected and quantiﬁed via Western blotting following a re-
action by 2,4-dinitrophenylhydrazine (DNPH) [52]. While there were no
differences in the quantity of carbonylated myocardial proteins be-
tween sham-operated SCOT-Heart-KO and aMHC-Cre mice (raw data
not shown, Figure 7C), following 4 wk TAC, pressure-overloaded
hearts of SCOT-Heart-KO mice exhibited a two-fold increase in the
quantity of carbonylated myocardial proteins, supporting a role for
ketone body oxidation in the diminution of ROS in the setting of
pressure overload injury (Figure 7C). These data indicate that the
absolute deﬁciency of myocardial ketone body oxidation is deleterious
during pressure overload-induced remodeling possibly due, at least in
part, to increased oxidative stress in the myocardium.
4. DISCUSSION
Normal heart muscle is relatively omnivorous, ﬂexibly converting the
energy stored in a diverse menu of substrates to high energy phos-
phates. Whereas myocardial glucose and fat utilization have been
extensively studied for their role in modulating cardiac function in
pathological states [4,5,53], the importance of ketone body meta-
bolism under both physiological and pathological conditions has not
been carefully scrutinized. Adherence of wild type mice to high fat, very
low carbohydrate ketogenic diets is well-tolerated and causes only
subtle hemodynamic effects. Using mice that exhibit loss of SCOT
speciﬁcally in cardiac myocytes, we determined the role of myocardial
ketone body metabolism under baseline conditions, and conditions
known to increase myocardial fat and ketone metabolism including
starvation and maintenance on a ketogenic diet. Hearts lacking the
ability to oxidize ketone bodies rely more heavily on fatty acid oxidation
when both fat and ketones are available as substrates. However, few
differences were found between SCOT-Heart-KO and control mice
during periods of increased reliance on fat and increased myocardial
ketone delivery, which indicates that the ability of the SCOT-Heart-KO
mice to convert the energy stored within fatty acids to high energy
phosphates protects from the loss of ketone body utilization, and that






























































































































Figure 6: Decreased acetylation of lysine residues in myocardial proteins of SCOT-Heart-KO mice. Decreased acetylation of lysine residues is evident at baseline in both (A) whole
myocardial and (B) isolated mitochondrial protein extracts as well as (C) after 4 wk TAC in whole myocardial extracts. n ¼ 5e7 mice/group, *p  0.05, **p  0.01, ***p  0.001
by Student’s t test.
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hearts. To determine how SCOT-Heart-KO mice adapt to pathological
states in which reliance on fatty acid oxidation is normally shifted
toward glucose metabolism, we employed experimental conditions
that diminish myocardial fatty acid oxidation, including the systemic
inﬂammatory response (LPS) and myocardial pressure overload (TAC).
In particular, while control mice exhibit compensated remodeling with
concentric LV hypertrophy and preserved ejection fraction in response
to pressure overload, SCOT-Heart-KO mice develop adverse ventricular
remodeling with LV dilation and reduced ejection fraction. Despite
systolic dysfunction, stroke volume and cardiac output were normal in
these experiments, due to the increased left ventricular end diastolic











































































































































Figure 7: Pressure-overload-induced signatures of increased oxidative stress in SCOT-Heart-KO mice. (A) H2O2 emission was measured in isolated mitochondria following the
addition of metabolic substrate (i) succinate, (ii) succinate plus D-bOHB, or (iii) succinate plus acetoacetate (AcAc); rotenone was added to eliminate further H2O2 emission.
*p ¼ 0.02 and p ¼ 0.04 for rates of H2O2 emission following the addition of succinate plus AcAc in SCOT-Heart-KO and aMHC-Cre mitochondria, respectively, when compared
with the rates of H2O2 emission following the addition of succinate alone, n ¼ 7 mice/group. (B) Tissue superoxide content was quantiﬁed in situ using ﬂuorogenic probes CellROX
Green, detecting mitochondrial and nuclear ROS and CellROX Deep Red reagent detecting cytosolic ROS. Relative intensity was quantiﬁed using ImageJ. Sham operated images
not shown. (C) Protein oxidation was quantiﬁed in whole myocardial lysates of SCOT-Heart-KO and aMHC-Cre mice via Western blotting following a reaction by 2,4-
dinitrophenylhydrazine (DNPH). Sham operated blot not shown. n ¼ 3e7 mice/group. ***p  0.001, ****p  0.0001 by 2-way ANOVA with Bonferroni post hoc analysis.




elimination of ketone bodies as an energy source drives hearts toward
a more adverse remodeling course of LV dilation [54].
Numerous studies have explored the complex relationship between
myocardial substrate utilization and pathological remodeling in the
hypertrophied heart e namely an increased reliance on glucose uti-
lization and concomitant reduction of fatty acid oxidative contribution to
energy production [55], and increased anaplerosis [56,57] (for a review
on myocardial anaplerosis, see Ref. [58]). These metabolic alterations
conspire to produce energetic inefﬁciencies in the hypertrophied and,
ultimately, failing heart [45]. Transgenic overexpression of GLUT1 in
the murine myocardium increases glucose utilization, attenuates
cardiac hypertrophy and maintains myocardial phosphocreatine and
ATP levels [59]. Genetically encoded increases in fatty acid oxidation
(via knockout of mitochondrial acetyl-CoA carboxylase) in hypertrophic
remodeling reveals a signiﬁcant reduction in hypertrophic growth and
ﬁbrosis, as well as a reduction in anaplerotic ﬂux, which were asso-
ciated with improved contractility in the pressure overloaded heart
[57]. Our study suggests (i) preservation of fatty acid oxidation in the
remodeling heart may be salutary, as long as ketone body oxidation is
preserved and (ii) a modest increase in anaplerosis in SCOT-Heart-KO
mice at baseline, in the absence of any hemodynamic abnormalities.
Thus, the inability to oxidize ketones may predispose the heart to
metabolic reprogramming that contributes to worsened remodeling
following pressure overload. While our data do not provide evidence
that indicates altered abundances of steady state acetyl-CoA pool sizes
in the absence of SCOT, future untargeted interrogations of the SCOT-
deﬁcient metabolome will reveal how metabolic redundancy supports
a compensated response to the absence of ketolytic capacity in
physiological states of robust myocardial ketone body delivery.
The induction of pressure overload hypertrophy is associated with
increased oxidative stress [24,60,61]. Hearts of SCOT-Heart-KO mice
exhibit increased signatures of oxidative stress following 4 wk TAC e
prior to the development of structural and hemodynamic abnormalities.
Thus, increased oxidative stress could play a causative role in the
remodeling course exhibited by the hearts of these mice. ROS cause
oxidative modiﬁcation of myocardial proteins and lipids, and create
bioenergetic insufﬁciency via uncoupling [62e66]. The mechanism of
ketone bodies and their metabolism to regulate myocardial ROS
abundance and oxidative stress is incompletely understood. Ketone
bodies may be more energetically favorable substrates than fatty acids,
in part through the maintenance of a favorable NADþ/NADH ratio as
well as their ability to maintain ubiquinone in the oxidized state, which
increases redox span in the electron transport chain and thus di-
minishes superoxide production and increases energy available for
ATP synthesis [22]. Several in vitro studies support this theory. For
example, equimolar D-bOHB and AcAc attenuates ROS abundance of
isolated neurons [67,68]. In our study, AcAc diminished the rate of
superoxide production in mitochondria isolated from hearts of both
SCOT-Heart-KO and control mice, which suggests that AcAc-mediated
suppression of mitochondrial superoxide emission is likely due to a
non-oxidative role of AcAc, whose mechanisms could include ROS
scavenging by AcAc, or diminished mitochondrial inner membrane
potential through non-oxidative mechanisms [23]. Finally, ketone
bodies and SCOT activity can potentially inﬂuence the balance of ROS
production and scavenging from mitochondrial and extra-
mitochondrial sources [69].
Our study also demonstrates a correlation between SCOT enzyme
activity and protein acetylation, with SCOT-Heart-KO mice exhibiting
signiﬁcant diminutions in acetylated lysine residues at baseline and
following 4 wk TAC. Numerous myocardial proteins are regulated by
this post-translational modiﬁcation, including critical mediators of
myocardial fatty acid oxidation, the TCA cycle, and the electron
transport chain [70,71]. SCOT itself has been identiﬁed in a number of
screens to identify mitochondrial proteins with numerous acetylation
sites [70,72]. Whether acetylation of SCOT impairs or enhances
enzyme activity has yet to be determined, however, a study in hy-
pertrophic rat models demonstrates that SCOT is hyperacetylated in
these rats relative to non-hypertensive controls [72]. The role of
mitochondrial deacetylase SIRT3 as an ampliﬁer of antioxidant defense
mechanisms in the remodeling heart underscores the intriguing
connection between myocardial protein acetylation and oxidative
stress [73,74], and thus the possibility that protein acetylation in-
ﬂuences the observed ROS phenotypes in pressure-overloaded hearts
of SCOT-Heart-KO mice will be a target of future investigation. Protein
acetylation is also a common modiﬁcation among sarcomeric proteins
that mediate contractility [70,75,76], and in vitro experiments indicate
that increased acetylation of these myosin isoforms correlates with
increased actin sliding velocity, suggesting that acetylation of me-
chanical proteins post-TAC may play an important homeostatic role
[76].
In some cell types, increased delivery of the ketone body D-bOHB
increases histone acetylation, which ameliorates oxidative stress
through an ability to increase transcription of Foxo3a and Mt2 via in-
hibition of Class I histone deacetylases [77]. In our study, we
demonstrated that despite the absence of SCOT in the myocardium,
serum ketone body concentrations do not differ compared with control
mice. Although myocardium is the highest ketone body consumer per
mass, other ketolytic tissues (e.g., brain, skeletal muscle) could in-
crease ketone body uptake and consumption to modulate circulating
ketone body concentrations. Nonetheless, no alterations in Foxo3a or
Mt2 mRNA myocardial abundances were detected in hearts of SCOT-
Heart-KO mice at baseline or following 4 wk TAC (data not shown).
5. CONCLUSIONS
These are the ﬁrst studies to systematically interrogate myocardial
responses of hearts unable to oxidize ketone bodies, during ketotic
states and non-ketotic pathological states. Our ﬁndings are consistent
with the notion that myocardial ketone body metabolism integrates the
response to myocardial injury, in part through the maintenance of
protein acetylation and ROS homeostasis. However, it is also important
to note that the normal heart may counter-regulate against ‘excessive’
metabolism of ketone bodies when increased delivery is sustained
[33]. Therefore, the clinical applicability of these studies still remains
incompletely deﬁned, and targeted studies must quantify the oxidation
of ketone bodies by the human remodeling heart to decipher whether
an optimal window of myocardial ketone metabolism could confer
myocardial protection from oxidative stress and adverse signaling,
while preventing adverse metabolic consequences of ‘excessive’ ke-
tone body oxidation, e.g., impaired metabolic ﬂexibility. Because
systemic ketone body metabolism, and thus myocardial delivery of
ketone bodies, can be dynamically modiﬁed through nutritional means,
understanding the role of ketone body metabolism in the injured and
remodeling heart may hold promising downstream diagnostic and
therapeutic implications.
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